Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America

被引:46
|
作者
Justo, Nahila [1 ,2 ]
Espinoza, Manuel A. [3 ]
Ratto, Barbara [3 ,4 ]
Nicholson, Martha [2 ]
Rosselli, Diego [5 ]
Ovcinnikova, Olga [6 ]
Marti, Sebastian Garcia [7 ]
Ferraz, Marcos B. [8 ]
Langsam, Martin [9 ]
Drummond, Michael F. [10 ]
机构
[1] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden
[2] ICON Plc, Real World Evidence Strategy & Analyt, Stockholm, Sweden
[3] Pontificia Univ Catolica Chile, Dept Publ Hlth, Santiago, Chile
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Pontificia Univ Javeriana, Clin Epidemiol & Biostat Dept, Bogata, Colombia
[6] ICON Plc, HTA Strategy & Analyt, London, England
[7] Inst Clin Effectiveness & Publ Hlth, Buenos Aires, DF, Argentina
[8] Univ Fed Sao Paulo, Sao Paulo, Brazil
[9] Univ Isalud, Buenos Aires, DF, Argentina
[10] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
关键词
big data; epidemiology; health policy; health technology assessment; Latin America; real-world evidence; TUBERCULOSIS; PREVALENCE; COUNTRIES; COLOMBIA; QUALITY; ACCESS; IMPACT; BRAZIL;
D O I
10.1016/j.jval.2019.01.014
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Real-world evidence (RWE) is increasingly used to inform health technology assessments for resource allocation, which are valuable tools for emerging economies such as in America. Nevertheless, the characteristics and uses in South America are unknown. Objectives: To identify sources, characteristics, and uses of RWE in Argentina, Brazil, Colombia, and Chile, and evaluate the context-specific challenges. The implications for future regulation and responsible management of RWE in the region are also considered. Methods: A systematic literature review, database mapping, and targeted gray literature search were conducted to identify the sources and characteristics of RWE. Findings were validated by key opinion leaders attending workshops in 4 South American countries. Results: A database mapping exercise revealed 407 unique databases. Geographic scope, database type, population, and outcomes captured were reported. Characteristics of national health information systems show efforts to collect interoperable data from service providers, insurers, and government agencies, but that initiatives are hampered by fragmentation, lack of stewardship, and resources. In South America, RWE is mainly used for pharmacovigilance and as pure academic research, but less so for health technology assessment decision making or pricing negotiations and not at all to inform early access schemes. Conclusions: The quality of real-world data in the case study countries vary and RWE is not consistently used in healthcare decision making. Authors recommend that future studies monitor the impact of digitalization and the potential effects of access to RWE on the quality of patient care.
引用
收藏
页码:739 / 749
页数:11
相关论文
共 50 条
  • [41] Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes
    Patorno, Elisabetta
    Schneeweiss, Sebastian
    Wang, Shirley V.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 : 45 - 59
  • [42] Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making
    Berger, Marc L.
    Sox, Harold
    Willke, Richard J.
    Brixner, Diana L.
    Eichler, Hans-Georg
    Goettsch, Wim
    Madigan, David
    Makady, Amr
    Schneeweiss, Sebastian
    Tarricone, Rosanna
    Wang, Shirley V.
    Watkins, John
    Mullins, C. Daniel
    [J]. VALUE IN HEALTH, 2017, 20 (08) : 1003 - 1008
  • [43] Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
    Berger, Marc L.
    Sox, Harold
    Willke, Richard J.
    Brixner, Diana L.
    Eichler, Hans-Georg
    Goettsch, Wim
    Madigan, David
    Makady, Amr
    Schneeweiss, Sebastian
    Tarricone, Rosanna
    Wang, Shirley V.
    Watkins, John
    Daniel Mullins, C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) : 1033 - 1039
  • [44] THE NATIONWIDE OSMED HEALTH-DB DATABASE. A TOOL TO SUPPORT HEALTHCARE DECISION-MAKING AND REAL-WORLD EVIDENCE GENERATION
    Esposti, Degli L.
    Saragoni, S.
    Sangiorgi, D.
    Buda, S.
    Cangini, A.
    Russo, P.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A693 - A693
  • [45] PATIENT SATISFACTION, ADHERENCE, COMPLIANCE, PERSISTENCE IN HEALTHCARE. PRELIMINARY REAL-WORLD EVIDENCE (RWE) IN A PRIVATE HEALTH INSURANCE IN LATIN AMERICA COUNTRY
    Bregola, E.
    Zimmer, L.
    Lakoski, J.
    Lima, C.
    Bazzo, D.
    Machado, C.
    Tanaka, G. K.
    Tanaka, F.
    Bregola, V
    Tanaka, E.
    [J]. VALUE IN HEALTH, 2018, 21 : S139 - S139
  • [46] Partition testing for real-world evidence studies
    Cafri, Guy
    Wood, Jennifer
    Gagne, Joshua
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (12) : 1280 - 1286
  • [47] A Prospective, Real-World Evidence Study of Hyperkalemia Management Decision Making: Design of the TRACK Study
    Hsia, Judith
    Shivappa, Nitin
    Bakhai, Ameet
    Bover, Jordi
    Butler, Javed
    Ferraro, Pietro Manuel
    Fried, Linda F.
    Schneider, Markus P.
    Tangri, Navdeep
    Winkelmayer, Wolfgang C.
    Bishop, Meredith S.
    Chen, Hungta
    Jarbrink, Krister
    Rzepa, Ewelina
    Bonaca, Marc P.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 932 - 932
  • [48] Multidimensional Evidence Generation and FDA Regulatory Decision Making Defining and Using "Real-World" Data
    Jarow, Jonathan P.
    LaVange, Lisa
    Woodcock, Janet
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (08): : 703 - 704
  • [49] CONTEXT MATTERS - A TAXONOMY OF REAL-WORLD DATA AND EVIDENCE TO SUPPORT HTA DECISION-MAKING
    Murphy, L. A.
    Mestre-Ferrandiz, J.
    Sola-Morales, O.
    de Pouvourville, G.
    Cunningham, D.
    Corry, S.
    Akehurst, R.
    [J]. VALUE IN HEALTH, 2020, 23 : S622 - S622
  • [50] Real-world evidence to support regulatory decision making: New or expanded medical product indications
    Franklin, Jessica M.
    Liaw, Kai-Li
    Iyasu, Solomon
    Critchlow, Cathy W.
    Dreyer, Nancy A.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (06) : 685 - 693